Mizhuo's Top Picks in Healthcare for July
Truist Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15
Analysts Are Betting On Wave Life Sciences Ltd. (NASDAQ:WVE) With A Big Upgrade This Week
What Analysts Are Saying About WAVE Life Sciences Stock
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $11 to $19
Express News | HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $15 Price Target
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Update: WAVE Life Sciences Discloses 'Positive' Phase 1b/2a Data From Huntington's Disease Treatment But Shares Fall on Neurofilament Concern
Express News | Wave Life Sciences Ltd : Leerink Partners Raises Target Price to $16 From $12
Express News | Wave Life Sciences Are Trading Lower. The Company Announced Results From Its Phase 1b/2a SELECT-HD Clinical Trial of WVE-003
Express News | Mizuho Reiterates Outperform on WAVE Life Sciences, Maintains $19 Price Target
WAVE Life Sciences Analyst Ratings
Express News | Wave Life Sciences Shares Reverse Premarket Gains, Last Down 8.2%
What's Going On With Wave Life Sciences Stock On Tuesday?
Nvidia Rebound Buoys Nasdaq as US Equity Futures Trade Mostly Higher Pre-Bell
WAVE Life Sciences Discloses 'Positive' Data From Phase 1b/2a Trial of WVE-003 to Treat Huntington's Disease
Express News | Wave Life Sciences Shares Jump 44.5% Premarket After Co's Therapy for Huntington's Disease Shows Positive Results in Early Stage Trial
Wave Life Sciences WVE Phase 1b/2a Data; Oragenics OGEN Offering
Wave Jumps on Trial Data for Huntington's Disease Therapy